Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK
AAIC 2026 features comprehensive coverage of therapeutic approaches for Alzheimer's disease and related dementias. With multiple disease-modifying therapies now approved, the conference focuses on optimizing current treatments, developing next-generation therapeutics, and exploring combination strategies.
¶ Approved and Near-Approved Antibodies
- Lecanemab (Leqembi): Real-world effectiveness data, ARIA management, long-term outcomes
- Donanemab: New analyses on amyloid removal rates, subpopulation responses
- Aduhelm (aducanumab): Post-approval data and clinical experience
- AL101 (GSK4527226): Progranulin enhancer Phase 1/2 results
- AC Immune candidates: Novel epitope targeting approaches
- Bispecific antibodies: Dual-targeting strategies
- BACE inhibitors: Lessons learned from previous trials
- Gamma-secretase modulators: Alternative amyloid-lowering strategies
- Amyloid aggregation inhibitors: Targeting oligomer formation
- Anti-tau antibodies: Various epitopes in clinical development
- Tau PET tracer therapeutics: Diagnostic-therapeutic pairs
- Oligomer-specific antibodies: Targeting toxic tau species
- Tau acetylation inhibitors: Restoring tau function
- Tau phosphorylation modulators: Kinase inhibitors and phosphatase activators
- Tau aggregation breakers: Disrupting fibril formation
- Synaptic Vesicle Cycling: Preserving neurotransmission
- Dendritic spine stabilizers: Maintaining neuronal connectivity
- Neurotrophic factors: BDNF and related approaches
- Multiple pathological pathways require simultaneous targeting
- Synergistic effects between different mechanisms
- Lower doses may reduce side effects
- Anti-amyloid + anti-tau: Simultaneous pathology reduction
- Anti-amyloid + anti-inflammatory: Addressing multiple disease drivers
- Disease-modifying + symptomatic: Combined approaches
¶ Priority Candidates
- GLP-1 receptor agonists: Insulin-GLP1 combo approaches
- SGLT2 inhibitors: Metabolic benefits in neurodegeneration
- Statins: Cholesterol modulation and neuroprotection
- Antihypertensives: Vascular contributions to dementia
- Phase 2/3 repurposing trials: Results expected at AAIC 2026
- Adaptive trial designs: Efficient evaluation strategies
- Patient selection: Biomarker-defined populations
- "From Monotherapy to Combination: The Future of AD Treatment"
- "Next-Generation Tau Therapeutics"
- "Repurposing FDA-Approved Drugs for Alzheimer's"
- Major trial results in Developing Topics sessions
- Novel mechanism presentations
- First-in-class therapeutic data